Pulse.

a daily field guide to health research that matters

◆ Console

‹ Wed · 11 Nov 2026
Standard addition

Sepsis in Chimeric Antigen Receptor T-Cell Therapy: A Six-Year Nationwide Analysis of Clinical Outcomes and Healthcare Resource Utilization in Hospitalizations for Hematologic Malignancies.

Infections during CAR T-cell therapy are rare but serious, occurring in 6% of hospitalizations with high mortality.

The study quantified the clinical burden of sepsis during CAR T-cell therapy hospitalizations. Sepsis occurred in 6.2% of hospitalizations and was associated with 28.7% in-hospital mortality versus 1.1% without sepsis.

What the study was

Study design
Retrospective nationwide hospitalization database study
Population
10450 weighted CAR T-cell therapy hospitalizations for hematologic malignancies
Sample size
10450
Category
Treatment Innovation
Maturity
Validated
Journal
Transplantation and cellular therapy

Why it surfaced

The large nationwide analysis identifies a major safety burden in CAR T care, though administrative data cannot establish causality

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.